

NOVO NORDISK A S  
Form 6-K  
April 25, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

April 24, 2018

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

\_\_\_\_\_

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

## **Novo Nordisk A/S – Reduction of the share capital**

**Bagsværd, Denmark, 24 April 2018** – At Novo Nordisk’s Annual General Meeting on 22 March 2018, it was decided to reduce the company’s B share capital from DKK 392,512,800 to DKK 382,512,800 by cancellation of part of the company’s portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 490,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 382,512,800.

The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced.

*Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube.*

## **Further information**

### *Media:*

Anne Margrethe Hauge +45 4442 3450 [amhg@novonordisk.com](mailto:amhg@novonordisk.com)  
Ken Inchausti (US) +1 609 786 8316 [kiau@novonordisk.com](mailto:kiau@novonordisk.com)

*Investors:*

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com  
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com  
Christina Kjær +45 3079 3009 cnje@novonordisk.com

**Novo Nordisk A/S**      Novo Allé      Telephone:      Internet:  
Investor Relations      2880 Bagsværd      +45 4444 8888      www.novonordisk.com  
Denmark      CVR no:  
24 25 67 90

Company announcement No 34 / 2018

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: April 24, 2018

Lars Fruergaard Jørgensen

Chief Executive Officer